Estimating the marginal cost of a life year in Sweden's public healthcare sector.


Journal

The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 15 11 2018
accepted: 12 02 2019
pubmed: 24 2 2019
medline: 14 1 2020
entrez: 24 2 2019
Statut: ppublish

Résumé

Although cost-effectiveness analysis has a long tradition of supporting healthcare decision-making in Sweden, there are no clear criteria for when an intervention is considered too expensive. In particular, the opportunity cost of healthcare resource use in terms of health forgone has not been investigated empirically. In this work, we therefore seek to estimate the marginal cost of a life year in Sweden's public healthcare sector using time series and panel data at the national and regional levels, respectively. We find that estimation using time series is unfeasible due to reversed causality. However, through panel instrumental variable estimation we are able to derive a marginal cost per life year of about SEK 370,000 (EUR 39,000). Although this estimate is in line with emerging evidence from other healthcare systems, it is associated with uncertainty, primarily due to the inherent difficulties of causal inference using aggregate observational data. The implications of these difficulties and related methodological issues are discussed.

Identifiants

pubmed: 30796552
doi: 10.1007/s10198-019-01039-0
pii: 10.1007/s10198-019-01039-0
pmc: PMC6602994
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-762

Références

J Health Econ. 2008 Jul;27(4):826-842
pubmed: 18261812
Health Econ. 2012 Mar;21(3):316-37
pubmed: 21322086
Qual Life Res. 2014 Mar;23(2):431-42
pubmed: 23975375
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi
pubmed: 25692211
Soc Sci Med. 2017 Apr;179:9-17
pubmed: 28237460
Pharmacoeconomics. 2018 Feb;36(2):239-252
pubmed: 29273843
Health Econ. 2018 Apr;27(4):746-761
pubmed: 29282798
Health Econ. 2018 Jun;27(6):1017-1023
pubmed: 29607571
Value Health. 2018 Aug;21(8):897-904
pubmed: 30098666
Eur J Health Econ. 2019 Mar;20(2):175-180
pubmed: 30187251
Soc Sci Med. 1987;25(5):427-41
pubmed: 3499669

Auteurs

Jonathan Siverskog (J)

Centre for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, 581 83, Linköping, Sweden. jonathan.siverskog@liu.se.

Martin Henriksson (M)

Centre for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, 581 83, Linköping, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH